Literature DB >> 6097665

Influence of food on the bioavailability of enalapril.

B N Swanson, P H Vlasses, R K Ferguson, P A Bergquist, A E Till, J D Irvin, K Harris.   

Abstract

In a randomized, two-period crossover study in 12 normal volunteers, serum and urine concentrations of the angiotensin-converting enzyme inhibitor enalapril and its active metabolite enalaprilat were determined following administration of a single 40-mg tablet of enalapril maleate administered both in the fasting state and with a standard breakfast. A 7-d interval separated the two treatment periods. Area under the serum concentration-time curves for enalaprilat and urinary recoveries for enalaprilat and total drug did not differ significantly between the fed and fasted conditions. The mean observed maximum serum concentration of enalaprilat was slightly higher for the fasting treatment, but the time to peak concentration was almost identical for the two treatments. Enalapril maleate is unlike the prototype angiotensin-converting enzyme inhibitor captopril in that a standard meal does not appear to influence absorption of this new drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097665     DOI: 10.1002/jps.2600731146

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Prodrugs.

Authors:  D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

3.  Absorption of oral enalapril in germ-free and microbially-associated rats.

Authors:  K Pelkonen; P Ylitalo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Apr-Jun       Impact factor: 2.441

4.  Short term haemodynamic effects of converting enzyme inhibition before and after eating in patients with moderate heart failure caused by dilated cardiomyopathy: a double blind study.

Authors:  B Herrlin; C Sylvén; O Nyquist; O Edhag
Journal:  Br Heart J       Date:  1990-01

Review 5.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

6.  Evidence for site-specific absorption of a novel ACE inhibitor.

Authors:  G M Grass; W T Morehead
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

Review 7.  Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics.

Authors:  G S Thind
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 8.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

9.  Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors.

Authors:  B Santos Ramos; M J Piña Vera; E Carvajal Gragera; M Atienza Fernández
Journal:  Pharm World Sci       Date:  1993-10-15

Review 10.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.